Vascular leak syndrome: a side effect of immunotherapy
- 1 October 1997
- journal article
- review article
- Published by Elsevier in Immunopharmacology
- Vol. 37 (2-3) , 117-132
- https://doi.org/10.1016/s0162-3109(97)00041-6
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- Clinical Toxicity of Cytokines Used As Haemopoietic Growth FactorsDrug Safety, 1995
- Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cystsJournal of Neurosurgery, 1995
- Systemic capillary leak syndromeJournal of the American Academy of Dermatology, 1995
- Interleukin-la Reduces the Severity of the Vascular Leak Syndrome Produced by Interleukin-2 and Interleukin-2 Plus Interferon-aToxicologic Pathology, 1994
- Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantationAnnals of Hematology, 1993
- Canine Jugular Vein Endothelial Cell Monolayers in vitro: Vasomediator-Activated Diffusive Albumin PathwayJournal of Vascular Research, 1993
- Clinical Toxicity of Interleukin-2Drug Safety, 1992
- Involvement of Thromboxane and Neutrophils in Multiple-system Organ Edema with Interleukin-2Annals of Surgery, 1990
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Histamine release in paediatric cardiopulmonary bypass —a possible role in the capillary leak syndromeInflammation Research, 1987